Preliminary programme

in this version of the programme, only the presenter's name is indicated, please consider timing by Central European Summer Time titles below are shortened, point a title with your mouse to reveal it
Detailed instructions for speakers and poster presenters
____hello, we are
coming soon

Thursday, 3 June

Opening ceremony
  • Greeting of Guests
  • Kininogen(s) structure and function ’For HAE Patients’ awarded Allen P. Kaplan USA, introduced by Anthony Castaldo USA
  • Welcome music performance
Opening lecture I

The COVID-19 Bradykinin Storm — Confronting the COVID-19 pandemic with supercomputing, Explainable-AI and systems biology Daniel Jacobson USA

Opening lecture II

Global initiatives in HAE – The revision and update of the WAO/EAACI guideline for HAE and the ACARE networkMarcus Maurer Germany

Opening lecture III

Factor XII self-controlCoen Maas The Netherlands


Friday, 4 June

Opening lecture IV

The integrative role of endothelial cells in bradykinin-mediated angioedema László Cervenak Hungary

Session I
Basic research, diagnostics
  • PHA-022121: Efficacy in a monkey bradykinin challenge model translated to human Anne Lesage Switzerland
  • Investigation of neutrophil granulocyte function in patients with Hereditary Angioedema Erika Kajdácsi Hungary
  • Detection of C1-inhibitor/C1-inhibitor antibody complexes and its connection with underlying diseases of acquired angioedema Zsófia Pólai Hungary
  • Activation of MASP-3 by PCSK6 links the complement and the proprotein convertase systems in the blood József Dobó Hungary
  • Intravascular Bradykinin formation is modulated by the combined presence of pk, HK, C1INH, and PRCP Alvin Schmaier United States
11:30 Break
Session II
  • Preclinical studies of BMN 331 in mice and non-human primates demonstrate continuous, clinically meaningful production of C1-INH and phenotypic correction, warranting evaluation of this AAV-mediated gene therapy for treatment of Hereditary Angioedema in humans Jill Woloszynek United States
  • NTLA-2002: CRISPR-Mediated Gene Knockout of KLKB1 as a potential single-dose treatment for Hereditary Angioedema (HAE) James Butler United States
  • The constellation of SERPING1 variants associated with C1-INH-HAE Christian Drouet France
  • Understanding disease mechanisms of Hereditary Angioedema through rna seq transcriptome profiling Jonathan A Bernstein United States
13:30 Lunch break
Opening lecture V

Tissue kallikrein, kinins and ACE (kininase II) in cardiovascular and renal diseases: the friendly side of kinins François Alhenc-Gelas France

Session III
Clinical aspects
  • Heart-rate variability evaluation during attacks in patients with Hereditary Angioedema due to C1-Inhibitor deficiency Francesca Perego Italy
  • Pregnancy outcome in patients with Hereditary Angioedema: A single center experience from North India Ankur Jindal India
  • Prodromes predict oncoming HAE attacks: results of a prospective study Iris Leibovich-Nassi Israel
  • New concepts in the classification of angioedema syndromes Avner Reshef Israel
16:45 Break
Poster session I
  • HAE Junior: A patient organization with a holistic approach Camelia Isaic Czech Republic
  • Lanadelumab efficacy is sustainable over time: Findings from the HELP and HELP OLE studies Emel Aygören-Pürsün Germany
  • Reimbursement of the C1-Inhibitor esterase laboratory testing facilitates the early diagnosis of Hereditary Angioedema Noémi-Anna Bara Romania
  • Efficacy of subcutaneous C1-inhibitor long-term prophylaxis in C1-INH-HAE Ana Entrala Spain
  • Predicting clinical benefits of bradykinin B2 receptor ligands using the human umbilical vein contractility assay François Marceau Canada
  • Searching for genetic biomarkers for Hereditary Angioedema due to C1-inhibitor deficiency (C1-INH-HAE) Anastasios E. Germenis Greece
  • Laryngeal attack in Hereditary Angioedema in the emergency room: a case report Benítez Lima, Ana Karen Mexico
  • Detailed long term follow-up of a patient with acquired angioedema due to C1-inhibitor deficiency Zsófia Pólai Hungary
  • A spectrum of Serping1 mutations and clinical characterisation of Czech Hereditary Angioedema patients Hana Grombirikova Czech Republic
  • Clinical and genetic diversity of Hereditary Angioedema in Latvia Adine Kanepa Latvia
18:45 'In memoriam' Michael Frank, Marco Cicardi, Jose Fabiani
Virtual Budapest sightseeing


Saturday, 5 June

Opening lecture VI

Novel types of Hereditary AngioedemaKonrad Bork Germany

Session IV
Treatment & Clinical trials
  • Recombinant human C1 esterase inhibitor as prophylaxis for idiopathic non-histaminergic angioedema Mehran Alizadeh Aghdam The Netherlands
  • Diagnosis of Hereditary Angioedema in Latin America is improving, however specific lab tests and therapies for many countries are not available Anete Sevciovic Grumach Brazil
  • Long-term safety and efficacy of Berotralstat in Hereditary Angioedema (HAE): special considerations in patients transitioning from androgens Marcin Stobiecki Poland
  • Garadacimab, a novel monoclonal antibody targeting activated factor XII (FXIIa), prevents attacks in patients with Hereditary Angioedema (HAE) Markus Magerl Germany
  • Fast improvement of Hereditary Angioedema (HAE) attacks with the oral on-demand plasma kallikrein inhibitor KVD900: an analysis of the pharmacokinetic and pharmacodynamic profile of KVD900 and attack symptom severity during a double-blind, randomized phas Andrea Zanichelli United Kingdom
11:30 Break
Session V
Case reports
  • ‘C1 inhibitor normal’ versus ‘C1 inhibitor deficient’ Hereditary Angioedema: A false dichotomy? Samantha Chan Australia
  • Covid19 in HAE patients – case series from a single centre John Dempster United Kingdom
  • Bariatric surgery in patients with Hereditary Angioedema due to C1-inhibitor deficiency David Loli-Ausejo Spain
  • Hereditary Angioedema: a case report Natalja Kurjane Latvia
  • Acquired Angioedema secondary to prostate cancer treated with lanadelumab Babak Aberumand Canada
13:45 Lunch break
Session VI
QoL & COVID-19
  • Angioedema Quality of Life Questionnaire (AE-QoL) - How to interpret its scores Karsten Weller Germany
  • Lifestyle medicine for Hereditary Angioedema Erik van den Top New Zealand
  • Psychiatric and clinical characteristics of Hereditary Angioedema patients who experienced attacks during COVID-19 Nihal Gökmen Turkey
  • Use of subcutaneous human C1 esterase inhibitor concentrate as long -term prophylaxis therapy in patients with Hereditary Angioedema with C1 inhibitor deficiency during the COVID19 pandemic period Krasimira Baynova Spain
  • Latin-American Hae individuals with abnormal C1 Inhibitor infected by SARS Cov2 showed mild clinical manifestations Ricardo Dario Zwiener Colombia
  • Quality of life on some Colombian Hae Patients Jairo Rodriguez Colombia
16:45 Break
Poster session II
  • Impact of Lanadelumab in Hereditary Angioedema: A case series of 12 patients in Canada Aled Iaboni Canada
  • Living with HAE in Australia – Initial findings from a national observational study Constance Katelaris Australia
  • Angioedema and low C4 as initial manifestations leading to the diagnosis that is even rarer than HAE Sladjana Andrejevic Serbia
  • Novel genetic modifiers of the clinical phenotype in patients with Hereditary Angioedema due to C1 inhibitor deficiency Nina Rupar Slovenia
  • Overview of SERPING1 variations identified in Hungarian patients with Hereditary Angioedema Dorottya Csuka Hungary
  • SERPING1 gene promoter variation in Turkish patient with HAE Aycan Aşik Turkey
  • Real-world effectiveness and disease/treatment management associated with lanadelumab long-term prophylaxis in HAE: design for a retrospective chart review Markus Magerl Germany
  • Burden of illness and treatment patterns in patients with Hereditary Angioedema type I and II: A retrospective observational chart review Henriette Farkas Hungary
  • HAE treatment – Single or multiple pathways to the rescue? Anna Valerieva Bulgaria
  • Can HAE patients with C1INH deficiency be completely alleviated from disease symptoms? Yes, we can! Hilary Longhurst New Zealand
  • Successful prophylactic recombinant human C1-esterase inhibitor for the treatment of Idiopathic non-histaminergic angioedema (iNHAE): a case report Mehran Alizadeh Aghdam The Netherlands
Virtual Banquet


Sunday, 6 June

Session VII
National surveys
  • A national audit of Hereditary and Acquired Angioedema in New Zealand 2015-2019 Ke Li Chow New Zealand
  • Characterization of Hereditary Angioedema due to mutations in the F12 gene in seven Spanish families Francisca Vílchez-Sánchez Spain
  • Clinical and therapeutic characteristics of adult patients with idiopathic angioedema Mehran Alizadeh Aghdam The Netherlands
  • The characteristics and the incidence of upper airway edema in patients with Hereditary and acquired angioedema with C1 inhibitor deficiency Zsuzsanna Balla Hungary
  • Diagnosing pediatric patients with Hereditary C1-inhibitor deficiency – experience from the Hungarian Angioedema Center of reference and excellence Noémi Andrási Hungary
  • Clinical and demographic characteristics of patients with Hereditary Angioedema in Canada Erika Lee Canada
  • This is HAE International Anthony Castaldo, Henrik Balle Boysen United States
11:00 Break
’Grant for Young Investigators’ Ceremony
Closing remarks
  • Anastasios E. Germenis Greece